R
TransCode Therapeutics (RNAZ)
$000.00 0.00% ($0.00)
- Today
- Week
- Month
- Year
- 5 Year
- YTD
getbaraka.com
About TransCode Therapeutics (RNAZ)
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovar... Read more
- USD7.07
- USD7.20
- USD6.82
- USD1.03k
- -16.40%
- --
- 1.00
- 41.23k
- 6M
- 6.15
- -99.30%
Stock News
3 hours ago
Warehousing and Storage Services Market Outlook: Trends and Forecasts to 2030 Featuring DHL International, XPO Logistics, Ryder System, and Other Industry Leaders
Yahoo
6 hours ago
Broadcom: Premium Price Warrants A Pause; Downgrade To Hold
SeekingAlpha
7 hours ago
AudioCodes: Margins Improve, But Growth Still Missing
SeekingAlpha
8 hours ago
Institutional Investors Ramp Up U.S. Stock Selling In May
SeekingAlpha
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
